or Try an Advanced Search...

    Technical Analysis for MEIP - MEI Pharma, Inc.

    Grade Last Price % Change Price Change
    D 2.80 -2.10% -0.06
    MEIP closed down 2.1 percent on Wednesday, November 20, 2024, on 58 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical MEIP trend table...
    Date Alert Name Type % Chg
    MACD Bearish Centerline Cross Bearish 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Resistance Bearish -2.10%
    Stochastic Reached Oversold Weakness -2.10%
    Inside Day Range Contraction -2.10%
    Down 3 Days in a Row Weakness -2.10%
    Down 4 Days in a Row Weakness -2.10%
    Older End-of-Day Signals for MEIP ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 17 hours ago
    Possible NR7 about 18 hours ago
    60 Minute Opening Range Breakout about 20 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    Down 2 % about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    MEIP Chart by TradingView
    Basic chart:

    Profile

    MEI Pharma, Inc. Description

    MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Clinical Development Treatment Of Cancer Virotherapy Novogen Histone Deacetylase Inhibitor Refractory Solid Tumors

    Is MEIP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 17 Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
    Nov 13 MEI Pharma GAAP EPS of -$1.20
    Nov 12 MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
    Oct 28 MEI Pharma stock jumps 8% on sale of drug asset ME-344
    Sep 19 MEI Pharma GAAP EPS of $2.67 misses by $0.95, revenue of $65.3M in-line
    Sep 19 MEI Pharma Reports Fiscal Year End 2024 Cash Position
    Aug 12 MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
    Jul 23 Laidlaw cuts MEI Pharma to hold over shutdown concerns
    Jul 22 MEI Pharma plans workforce reduction as part of strategic alternatives
    Jul 22 MEI Pharma to Consider Strategic Alternatives
    See more MEIP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.9099
    52 Week Low 2.61
    Average Volume 51,688
    200-Day Moving Average 3.27
    50-Day Moving Average 2.90
    20-Day Moving Average 3.00
    10-Day Moving Average 2.98
    Average True Range 0.13
    RSI (14) 37.89
    ADX 26.03
    +DI 15.28
    -DI 23.89
    Chandelier Exit (Long, 3 ATRs) 2.92
    Chandelier Exit (Short, 3 ATRs) 3.08
    Upper Bollinger Bands 3.26
    Lower Bollinger Band 2.74
    Percent B (%b) 0.12
    BandWidth 17.25
    MACD Line 0.00
    MACD Signal Line 0.03
    MACD Histogram -0.0309
    Fundamentals Value
    Market Cap 18.66 Million
    Num Shares 6.66 Million
    EPS 6.17
    Price-to-Earnings (P/E) Ratio 0.45
    Price-to-Sales 0.30
    Price-to-Book 0.39
    PEG Ratio 20.60
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.94
    Resistance 3 (R3) 2.94 2.89 2.91
    Resistance 2 (R2) 2.89 2.86 2.89 2.90
    Resistance 1 (R1) 2.85 2.84 2.83 2.85 2.90
    Pivot Point 2.80 2.80 2.79 2.80 2.80
    Support 1 (S1) 2.76 2.77 2.74 2.76 2.70
    Support 2 (S2) 2.71 2.75 2.71 2.70
    Support 3 (S3) 2.67 2.71 2.69
    Support 4 (S4) 2.67